Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of DV201P-RNA and DV202B1-RNA in Adults Without HIV
NCT07390474Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of DV201P-RNA and DV202B1-RNA in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Local reactogenicity at Day 295, Systemic reactogenicity at Day 295 and 7 more. Started Mar 2026; status: recruiting.
02
Drugs
DV201P-RNADV202B1-RNA
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07390474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07390474.